Zenas BioPharma, Inc. (ZBIO)
Nasdaq · Healthcare · Biotechnology
$27.83−1.64%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.8B
- 52-week range
- $13.50 – $44.60
- 52-week change
- +22.86%
- EPS (trailing)
- −$9.63
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $10.0M (+100.00%)
- Net income
- −$378M
- Operating margin
- −3830.6%
- Diluted EPS
- −$8.44
- Free cash flow
- −$172M
From the company’s annual report on SEC EDGAR.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Headquarters: Waltham, United States · 167 employees · zenasbio.com